

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original): A method of identifying a substance suitable for use in the treatment of a leukocyte-associated inflammatory disease which modulates the activity of a polypeptide encoded by the human transient receptor potential 6 gene, wherein the method comprises combining a candidate substance with said polypeptide and measuring the effect of the candidate substance on the activity of said polypeptide.

Claim 2. (original): A method according to claim 1 wherein the candidate substance is combined with cells that are stably-transfected with TRPC6 and express a functional TRPC6 channel and measuring any membrane depolarisation to indicate a TRPC6-mediated Na⁺ influx.

Claim 3. (original): A method according to claim 1 wherein the cells express an endogenous calcium-mobilising G protein-coupled receptor that can activate TRPC6 channels by agonist stimulation and a receptor agonist is added after the candidate substance to stimulate the TRPC6 channels and allow for any inhibition to be measured.

Claim 4. (withdrawn): A pharmaceutical composition comprising a compound that inhibits the influx of calcium ions through a human TRPC6 ion channel and a pharmaceutically acceptable carrier.

Claim 5. (withdrawn): A pharmaceutical composition according to claim 4 wherein the compound is 1-[b-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole·HCl.

Claim 6. (withdrawn): A method of treating a leukocyte-associated inflammatory disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of an antibody which is immunoreactive with a polypeptide encoded by the human TRPC6 gene or an antisense oligonucleotide comprising a nucleotide sequence complementary to a polynucleotide comprising a nucleotide sequence encoding that polypeptide.

Claim 7. (withdrawn): The method according to claim 6, in which the disease is a neutrophil-associated disease such as chronic obstructive pulmonary disease, adult respiratory distress syndrome, rheumatoid arthritis or inflammatory bowel disease.

Claim 8. (withdrawn): The method according to claim 6, in which the disease is an eosinophil-associated disease such as asthma or allergic rhinitis.

Claim 9. (withdrawn): A method of treating a leukocyte-associated inflammatory disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a TRPC6 inhibitor.

Claim 10. (withdrawn): A method of treating pulmonary hypertension in a subject in need of such treatment, which comprises administering to said subject an effective amount of a TRPC6 inhibitor.